Later, the identification of increased IL17 production by T helper cells in the peripheral blood of RA patients who did not adequately respond to TNFi provided a rationale for evaluating the effect of remtolumab (ABT-122) in RA (19). This evidence concerns the gene IL17A and rheumatoid arthritis.